Alpine Immune Sciences (NASDAQ:ALPN) Stock Rating Lowered by SVB Leerink

SVB Leerink lowered shares of Alpine Immune Sciences (NASDAQ:ALPN - Free Report) from an outperform rating to a market perform rating in a report published on Friday morning, Marketbeat Ratings reports. The brokerage currently has $65.00 price target on the biotechnology company's stock, up from their previous price target of $42.00.

Several other research analysts have also weighed in on the company. Oppenheimer reaffirmed an outperform rating and issued a $44.00 target price (up from $33.00) on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. Wolfe Research reaffirmed a peer perform rating on shares of Alpine Immune Sciences in a research report on Thursday. Wedbush lowered Alpine Immune Sciences from an outperform rating to a neutral rating in a research report on Thursday. Royal Bank of Canada reaffirmed a sector perform rating and issued a $65.00 target price (up from $41.00) on shares of Alpine Immune Sciences in a research report on Thursday. Finally, HC Wainwright lowered Alpine Immune Sciences from a buy rating to a neutral rating in a research report on Thursday. Six investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of Hold and a consensus price target of $50.33.

Alpine Immune Sciences Trading Down 0.0 %

Shares of Alpine Immune Sciences stock traded down $0.03 during trading hours on Friday, reaching $64.37. 4,098,729 shares of the company's stock were exchanged, compared to its average volume of 1,839,320. The firm has a market capitalization of $4.22 billion, a price-to-earnings ratio of -100.83 and a beta of 1.14. The company has a fifty day moving average of $35.68 and a 200-day moving average of $22.60. Alpine Immune Sciences has a 52-week low of $6.71 and a 52-week high of $64.57.

Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report) last issued its earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.47. The business had revenue of $30.85 million for the quarter, compared to analyst estimates of $6.90 million. Alpine Immune Sciences had a negative return on equity of 15.54% and a negative net margin of 54.66%. On average, equities research analysts anticipate that Alpine Immune Sciences will post -1.76 earnings per share for the current fiscal year.

Institutional Trading of Alpine Immune Sciences

Several large investors have recently modified their holdings of the business. Banque Cantonale Vaudoise acquired a new stake in shares of Alpine Immune Sciences during the first quarter valued at about $798,000. HighPoint Advisor Group LLC acquired a new stake in shares of Alpine Immune Sciences during the fourth quarter valued at about $290,000. Vanguard Group Inc. grew its stake in shares of Alpine Immune Sciences by 51.5% during the fourth quarter. Vanguard Group Inc. now owns 2,234,767 shares of the biotechnology company's stock valued at $42,595,000 after acquiring an additional 759,888 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Alpine Immune Sciences by 176.6% during the fourth quarter. Wellington Management Group LLP now owns 109,882 shares of the biotechnology company's stock valued at $2,094,000 after acquiring an additional 70,151 shares in the last quarter. Finally, American International Group Inc. grew its stake in shares of Alpine Immune Sciences by 2.2% during the fourth quarter. American International Group Inc. now owns 16,185 shares of the biotechnology company's stock valued at $308,000 after acquiring an additional 343 shares in the last quarter. 75.17% of the stock is currently owned by institutional investors and hedge funds.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.